Evidence Level V — Preclinical Only, and Thinner Than It May Appear Online
Pinealon has a small, genuinely peer-reviewed literature — but nearly every study identified traces back to Vladimir Khavinson's own laboratory or direct collaborators, with no independent replication by an outside research group. The one identified human study is a small (n=32), uncontrolled, unblinded cohort that combined Pinealon with a second peptide (Vesugen), which means it cannot isolate Pinealon's effect at all. Retail and biohacker content about Pinealon substantially outweighs — and in places misrepresents — the primary literature. This profile states plainly where the evidence ends and where marketing claims begin.
Identity & Regulatory Status
St. Petersburg Institute of Bioregulation and Gerontology · Unconfirmed Registration
Origin
Khavinson "Short Peptide Bioregulator" Family
Pinealon is a tripeptide developed by Vladimir Khavinson's group, part of a family of short synthetic peptides (with Epithalon and Cortagen among others) proposed to act as tissue-specific "bioregulators." We could not verify a US or EU patent specifically covering the Glu-Asp-Arg sequence — a related Khavinson patent covers different tetrapeptide sequences, not this one. An Israeli patent referencing a neuron-regeneration tripeptide may be relevant, but its exact sequence could not be confirmed from available sources.
Patent coverage for this exact sequence: unconfirmed
Regulatory Status
No Confirmed Registration Identified
Unlike Epithalamin (an injectable Khavinson-family product with documented Russian pharmaceutical/clinical use) or Selank and Semax (both with confirmed Russian pharma registration), no specific Russian nutraceutical or pharmaceutical registration for Pinealon itself could be confirmed. Not evaluated or approved by the FDA. Sold in the US only as an unregulated research chemical.
No FDA evaluation · no confirmed Russian registration
Pinealon Sequence (N→C Terminal) — Tripeptide
E
1
D
2
R
3
Full Name
Glu-Asp-Arg
CAS Number
175175-23-2
Molecular Weight
418.4 Da
Family
Khavinson short-peptide bioregulator
Proposed Mechanism
Nuclear/Chromatin-Binding Hypothesis · Not a Classical Receptor Ligand
Khavinson's "short peptide theory" proposes that these tri-/tetrapeptides penetrate the cell nucleus and bind DNA in a tissue-specific way, acting as epigenetic-level regulators of gene expression rather than through a surface receptor. This is a real, published hypothesis — and it remains substantially unconfirmed as established cellular biology.
Central Hypothesis
Nuclear Penetration & DNA Minor-Groove Binding
An in vitro study (Fedoreyeva et al.) showed fluorescence-labeled short peptides penetrating cell nuclei and interacting with DNA. A 2021 molecular docking study proposed Pinealon binding near genes including CASP3, APOE, and SOD2 in a mouse Alzheimer's model.
Docking model + one nuclear-penetration study — not confirmed chromatin biology
Proposed Downstream Effect
Free-Radical Reduction / Cell Viability
Cell-culture data (Khavinson 2011, Rejuvenation Research) reported reduced free-radical levels and increased neuronal viability with Pinealon exposure.
Single cell-culture study, originating laboratory
Proposed Downstream Effect
Dendritic Spine Preservation (Mouse Model)
The 2021 Pharmaceuticals study reported modest (~11–13%) dendritic spine preservation in a 5xFAD Alzheimer's mouse model with Pinealon treatment.
One mouse model, originating laboratory
What This Mechanism Is Not: Pinealon does not have a confirmed receptor-binding partner, a confirmed pharmacokinetic profile, or independently replicated chromatin-binding evidence. The nuclear/DNA-binding theory is a genuine research hypothesis from a specific laboratory tradition — it should be presented as exactly that, not as settled mechanism.
Routes of Administration
Intranasal Discussed in Secondary Sources — No Formal Pharmacokinetic Data
Intranasal — Most Commonly Discussed Route
Discussed in vendor and community sources by analogy to other small Khavinson-family and Russian-tradition peptides (e.g., Semax, Selank), which are legitimately intranasal
No published human or animal pharmacokinetic study specific to intranasal Pinealon was identified
Other Routes
No published data on subcutaneous, oral, or other routes for Pinealon specifically
Evidence Review
All Level V or Below · Predominantly Khavinson Laboratory
Correction to a Common Online Claim: Pinealon is frequently described online as having evidence in "retinal ischemia" models. That claim traces to Epithalon, a related but distinct Khavinson-family peptide with its own retinitis pigmentosa research — not to Pinealon. This is a common conflation in secondary/marketing sources that we are correcting here rather than repeating.
Level V · In Vitro
Free-Radical Reduction & Cell Viability
Khavinson V et al. · Rejuvenation Research 2011
Cultured neurons exposed to Pinealon showed reduced free-radical markers and increased viability vs. untreated controls.
Originating laboratory; no independent replication identified.
Level V · Rodent
Prenatal Hyperhomocysteinemia — Cognitive Outcome in Offspring
Arutjunyan A et al. · Int J Clin Exp Med 2012;5(2):179-85
Rat offspring exposed to prenatal hyperhomocysteinemia showed improved cognitive measures with Pinealon vs. untreated offspring.
Model relevance to typical adult research-compound use is indirect at best.
Level V · Rodent
Carotid Occlusion (Cerebral Ischemia) in Aged Rats
Originating laboratory group
Measured behavioral outcomes and caspase-3 (apoptosis marker) after carotid occlusion in old rats.
This is the study most likely responsible for the "cerebral ischemia" association — legitimately Pinealon, unlike the retinal-ischemia claim above.
Level V · Mouse Model
5xFAD Alzheimer's Model — Dendritic Spine Preservation
Khavinson V et al. · Pharmaceuticals 2021;14(6):515
Modest (~11–13%) preservation of dendritic spine density in a transgenic Alzheimer's mouse model.
Paired with the molecular docking mechanism study discussed above; same laboratory.
Meshchaninov VN et al. · Advances in Gerontology 2015;28(1):62-7
32 patients, ages 41–83, with chronic polymorbidity and organic brain syndrome, treated with Pinealon combined with a second peptide (Vesugen).
No randomization, no blinding, no control group — this is an observational case series, not a clinical trial by any modern standard.
Because two peptides were co-administered, this study cannot isolate Pinealon's individual contribution even on its own terms.
The Independence Gap
No independent replication identified. Every study located is authored or co-authored by Khavinson or his direct laboratory collaborators. No outside research group has independently reproduced any Pinealon finding.
No controlled human trial exists. The single human data point is an uncontrolled 32-person cohort using a two-peptide combination, not Pinealon alone.
Retail claims outpace the literature. Numerous near-identical vendor "peptide guide" pages make specific benefit claims that are not traceable to any of the roughly half-dozen primary papers identified. Treat those claims as marketing copy, not evidence.
Editorial position: Pinealon has a real but very thin, single-laboratory preclinical literature and no meaningful human evidence. It belongs in the most cautious tier of compounds this platform discusses.
Pinealon vs. Epithalon
Same Laboratory Tradition, Different Molecules — Frequently Confused
Pinealon and Epithalon are both Khavinson-family bioregulator peptides and share the same theoretical framework, but they are not interchangeable, and their evidence bases target different tissues.
Feature
Pinealon
Epithalon
Sequence
Glu-Asp-Arg (tripeptide)
Ala-Glu-Asp-Gly (tetrapeptide)
Proposed target tissue
CNS / neuronal, general
Pineal gland / telomerase / endocrine
Retinal ischemia data
Not applicable — commonly misattributed
Yes — Epithalon's own retinitis pigmentosa research
Human data quality
One uncontrolled, combined-peptide cohort
More extensive human use history in Russian clinical settings, still not Western RCT-level
Evidence level (this platform)
Level V
Level V
Preparation & Storage
General Peptide Handling — No Pinealon-Specific Stability Data Published
🧊
Lyophilized Form
Refrigerated Storage (General Practice)
As with other short synthetic peptides, lyophilized Pinealon is generally handled with refrigerated storage away from light and moisture. No compound-specific stability study was identified to confirm shelf-life claims made by vendors.
⚠️
Sourcing
Unregulated Market — No Independent Purity Verification
Like other Khavinson-family peptides, Pinealon is sold through unregulated research-chemical channels with no independent identity or purity verification available to consumers, and templated marketing copy is reused across many vendor sites.
Investigational Dosing
No Established Human Dose Exists
There Is No Dose-Finding Study for Pinealon. No controlled human trial has established a safe or effective dose. Ranges discussed in online communities are not derived from any published dose-response study and are not reproduced here.
Safety Profile
No Formal Toxicology or Human Safety Trial Identified
❓
Formal Toxicology
Not published
No dedicated toxicology study identified in the peer-reviewed literature
❓
Human Adverse Events
No systematic data
The single human cohort study did not report a structured adverse-event assessment
🤰
Pregnancy / Breastfeeding
Suppressed — no data
No safety data exists for pregnancy, lactation, or pediatric use
Candidate Framework
Given the Evidence Level, Caution Applies Broadly
✓Appropriate Framing
Discussed as an exploratory, preclinical-stage research compound with a specific theoretical mechanism, not a validated cognitive intervention
Considered only alongside full disclosure of the single-laboratory evidence limitation
✕Poor Fit
Anyone expecting the level of evidence available for Semax, Selank, or Cerebrolysin — Pinealon's evidence base is materially thinner
Pregnant, breastfeeding, or pediatric use — no data exists
What Would Move This Compound Up the Evidence Ladder
The Gaps Are Foundational, Not Incremental
V
Current Standing
Single-laboratory preclinical + one uncontrolled, combined-peptide human cohort
No independent replication at any level
IIb
Next step: independent replication
A non-Khavinson-affiliated laboratory reproducing the core nuclear-binding or neuroprotection findings
Ib
Then: a single-compound, controlled human trial
Pinealon alone (not combined with Vesugen or another peptide), randomized, with a defined dose and control arm
🔬
Independence Problem
The most basic obstacle: no outside laboratory has attempted or published a replication of the core findings.
🧪
Single-Agent Human Data
The only human study combined two peptides — a single-agent human study has never been conducted.
Frequently Asked Questions
Pinealon — Common Questions, Answered at the Evidence Level Above
Is Pinealon legal to buy or use?
Pinealon is not evaluated or approved by the FDA, and no confirmed Russian regulatory registration for Pinealon itself has been identified. In the United States it is currently sold only as an unregulated research chemical, not labeled or intended for human consumption. This profile does not constitute a recommendation to purchase or use it, and legal status can vary by jurisdiction.
What is a "peptide bioregulator," and does that framework have solid evidence?
"Peptide bioregulator" refers to Vladimir Khavinson's theory that short synthetic peptides like Pinealon penetrate the cell nucleus and bind DNA in a tissue-specific way, regulating gene expression rather than acting through a classical receptor. It is a genuine, published research hypothesis, but it remains substantially unconfirmed as established cellular biology, resting mainly on in vitro nuclear-penetration studies and molecular docking models from the originating laboratory tradition.
What does the research actually show for Pinealon specifically?
The literature includes a handful of studies — cell-culture work on free-radical reduction, rodent studies on hyperhomocysteinemia and carotid occlusion, and a 5xFAD Alzheimer's mouse model showing modest dendritic spine preservation — nearly all from Khavinson's own laboratory with no independent replication. The single human data point is an uncontrolled 32-person cohort that combined Pinealon with a second peptide (Vesugen), so it cannot isolate Pinealon's individual effect.
Is Pinealon FDA-approved?
No. Pinealon has not been evaluated or approved by the FDA for any use, and no confirmed foreign regulatory approval has been identified either. It is classified on this platform as Evidence Level V — preclinical only, with no controlled human trial.
What are the biggest safety unknowns?
No dedicated toxicology study has been published, and the one human cohort study did not report a structured adverse-event assessment. There is no safety data for pregnancy, breastfeeding, or pediatric use. Given these gaps, anyone considering peptide research of any kind should discuss it with a licensed physician rather than relying on vendor claims.
Does Pinealon's name mean it targets the pineal gland or circadian rhythm?
Not based on the published research. Despite the name, Pinealon's proposed target is general CNS/neuronal tissue rather than pineal-gland or circadian-specific pathways — that territory belongs to its lab-mate Epithalon, which has its own pineal/telomerase-focused evidence base. No study identified ties Pinealon specifically to melatonin production or circadian regulation.
SD
Dr. Scott DelBoccio, DMD
Author & Physician Reviewer · PeptideReport.ai
Dr. Scott DelBoccio, DMD is a retired dentist with thirty years of clinical practice — including a hormone-therapy and regenerative wellness practice built around individual bloodwork, national lecturing on advanced dental and surgical techniques, mentoring new dentists on practice management, and innovating dental and laser procedures now used throughout North America — who is now heavily involved in peptide research and development, building beginner-to-advanced optimization frameworks calibrated to the individual, and holds workshops and lectures on peptide therapeutics for other clinicians and researchers. Pinealon is a good test of this site's editorial standard: plenty of vendor pages will tell you more about this compound than the actual published literature supports. This profile draws a clear line between the roughly half-dozen genuine primary-source studies and the retail claims built on top of them — including correcting a common misattribution of Epithalon's retinal-ischemia data to Pinealon.